https://scholars.lib.ntu.edu.tw/handle/123456789/628841
標題: | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | 作者: | Ahn, Myung J Kim, Hye R CHIH-HSIN YANG Han, Ji-Yu Li, Jacky Yu-Chung Hochmair, Maximilian J Chang, Gee-Chen Delmonte, Angelo Lee, Ki H Campelo, Rosario G Gridelli, Cesare Spira, Alexander I Califano, Raffaele Griesinger, Frank Ghosh, Sharmistha Felip, Enriqueta Kim, Dong-Wan Liu, Yuyin Zhang, Pingkuan Popat, Sanjay Camidge, D Ross |
關鍵字: | ALK TKI-naive; Anaplastic lymphoma kinase; Clinical trial; First line; Tyrosine kinase inhibitor | 公開日期: | 十二月-2022 | 出版社: | CIG MEDIA GROUP, LP | 卷: | 23 | 期: | 8 | 起(迄)頁: | 720 | 來源出版物: | Clinical lung cancer | 摘要: | Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628841 | ISSN: | 1525-7304 | DOI: | 10.1016/j.cllc.2022.07.008 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。